Skip to content
Coral Laboratories logo

Coral Laboratories

524506 BSE
Price unavailable

Coral Laboratories (CORALAB) share price was ₹501.40 at the 28 Oct 2026 close; market capitalisation ₹179 Cr; P/E (TTM) 9.32; sector Healthcare. The share price rose 3.2% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 57.4% year on year to ₹29.62 Cr and net profit rose 110.6% year on year to ₹5.39 Cr (compared with Jun 2025). Promoters held 71.51% of Coral Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 61/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹501.40 +2.40 +0.48% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹179 Cr
P/E (TTM)
9.32
EBITDA
₹25.10 Cr
Return on Equity
7.83%
Debt to Equity
0.02
Book Value
₹585.75
EPS (TTM)
₹53.77
52W High
₹679.00
52W Low
₹360.00

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,659.0087.672,56,416 Cr15.300.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.1072.361,75,315 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.30108.071,18,182 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.0026.281,17,805 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.4034.661,11,714 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.9032.701,10,265 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Coral Laboratories (this company)
—9.32179 Cr0.860.41%7.83%10.91%107 Cr19 Cr
Median 8 companies₹1,767.5034.861,17,994 Cr4.710.51%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

61 Good
Overall score

Data confidence 100/100

Category scores

Quality Average 52
Returns, margins, earnings quality 22% weight
Valuation Strong 74
Cheap vs sector & own history 24% weight
Growth Poor 30
Sales & profit trajectory 9% weight
Financial Health Strong 84
Solvency, leverage, coverage 9% weight
Momentum Strong 68
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Stock is trading at 0.96 times its book value

Weaknesses

3
  • The company has delivered a poor sales growth of -2.31% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Earnings include an other income of Rs.10.3 Cr.

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-22.8% lower than 3Y

change over 1 year

Net Income Growth
-32.23% lower than 3Y

change over 1 year

Cash Flow Change
—

EBITDA Margin Change
-7.97%

change over 1 year Operating margin 18.53% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
13.55
23.15
18.08
28.89
31.66
32.23
22.99
28.13
18.82
19.03
21.56
26.48
29.62
Expenses
11.81
17
15.98
22.64
20.92
25.72
16.67
25.44
16.64
14.09
19.67
20.28
24.13
Operating Profit
1.74
6.15
2.1
6.25
10.74
6.51
6.32
2.69
2.18
4.94
1.89
6.2
5.49
OPM %
12.84%
26.57%
11.62%
21.63%
33.92%
20.2%
27.49%
9.56%
11.58%
25.96%
8.77%
23.41%
18.53%
Other Income
1.29
1.81
1.37
2
1.56
2.54
2.52
1.71
2.05
3.03
2.49
2.64
2.15
Interest
0
0
0
0
0.03
0.01
0.02
0.04
0.06
0.1
0
0.01
0.03
Depreciation
0.55
0.44
0.49
0.5
0.49
0.51
0.5
0.51
0.45
0.45
0.69
0.54
0.66
PBT
2.48
7.52
2.98
7.75
11.78
8.53
8.32
3.85
3.72
7.42
3.69
8.29
6.95
Tax %
26.21%
20.21%
27.52%
25.16%
25.21%
25.21%
26.08%
26.49%
31.18%
21.56%
24.93%
36.91%
22.45%
Net Profit
1.84
6
2.16
5.79
8.8
6.38
6.14
2.83
2.56
5.82
2.78
5.22
5.39
EPS (₹)
5.15
16.79
6.05
16.21
24.63
17.86
17.19
7.92
7.17
16.29
7.78
14.61
15.09
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
59
77
95
92
91
71
97
76
78
84
115
86
97
Expenses
47
60
72
77
79
65
81
67
74
67
89
71
78
Operating Profit
12
16
23
15
12
5
16
8
4
16
26
15
19
OPM %
21%
21%
24%
17%
14%
8%
16%
11%
4.9%
19%
23%
18%
19%
Other Income
3
3
3
4
5
6
4
6
7
6
8
10
10
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
3
2
2
2
2
2
2
2
2
2
2
2
2
PBT
12
17
25
18
16
9
18
12
8
21
32
23
26
Tax %
22%
29%
34%
31%
34%
22%
23%
24%
22%
24%
26%
29%
—
Net Profit
10
12
16
12
10
7
14
9
6
16
24
16
19
EPS (₹)
26.79
34.71
45.63
34.85
28.61
19.96
37.93
25.33
18.05
44.2
67.63
45.85
53.77
Div. Payout %
9%
9%
11%
6%
7%
0%
0%
0%
0%
0%
2%
4%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
4
4
4
4
4
4
4
4
4
4
4
Reserves
56
67
106
113
110
112
133
152
151
174
198
206
Borrowings
1
0
2
2
1
6
6
6
0
0
4
4
Other Liabilities
12
19
20
22
21
23
25
28
20
28
25
27
Total Liabilities
72
89
131
140
136
144
168
190
174
206
229
241
Fixed Assets
19
18
18
22
23
23
21
24
25
24
23
44
CWIP
0
0
0
0
0
0
0
2
0
0
2
0
Investments
1
5
39
45
28
25
33
46
41
50
52
46
Other Assets
52
67
74
73
84
97
112
118
108
132
152
150
Total Assets
72
89
131
140
136
144
168
190
174
206
229
241
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
5
11
13
-1
-4
1
6
13
-5
-1
16
Investing
0
-3
-10
-13
3
-2
0
-6
-3
1
0
-18
Financing
0
0
0
-3
-1
4
0
0
-6
0
3
0
Net Cash Flow
0
2
1
-2
1
-2
1
0
4
-4
1
-2
Free Cash Flow
-1
4
9
9
-4
-5
0
1
11
-6
-4
-5
CFO/OP
30
70
85
124
31
-59
28
127
383
-4
23
150
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
152
132
117
125
122
178
148
184
109
123
107
125
Inventory Days
110
110
155
120
116
176
158
169
100
149
68
211
Days Payable
66
80
75
87
91
129
108
81
34
130
46
103
Cash Conversion Cycle
196
162
197
157
146
225
198
272
176
142
129
233
Working Capital Days
194
179
164
161
171
241
178
222
221
183
140
203
ROCE %
22%
27%
28%
16%
13%
8%
13%
7%
5%
13%
17%
11%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Coral Laboratories insights

65 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Promot.71.51%Others8.86%Public19.63%As ofSep 2026

Documents

Frequently Asked Questions about Coral Laboratories

What does Coral Laboratories Ltd do?
Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]
Where is Coral Laboratories Ltd (CORALAB) listed?
Coral Laboratories Ltd trades under code 524506 on the BSE.
Which sector does Coral Laboratories Ltd belong to?
Coral Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Coral Laboratories Ltd?
Coral Laboratories Ltd has a market capitalisation of ₹179.01 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Coral Laboratories Ltd?
Coral Laboratories Ltd trades at a PE ratio of 9.32 as of 28 Oct 2026, on earnings per share of ₹53.77, against a book value of ₹585.75 per share.
What is the 52-week high and low of Coral Laboratories Ltd?
Over the last 52 weeks Coral Laboratories Ltd has traded between ₹360 and ₹679 as of 28 Oct 2026.
Does Coral Laboratories Ltd pay dividends?
Coral Laboratories Ltd has a dividend yield of 0.40%.
What is the Return on Equity (ROE) of Coral Laboratories Ltd?
Coral Laboratories Ltd reported a return on equity of 7.83%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]

Website corallab.com
Face Value ₹ 10
Shares Outstanding 35,70,248

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524506.md for Coral Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month